Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 11, 1999, Pages 2498-2505

  Dueñas, Zulma ^a,b,c   Torner, Luz ^a   Corbacho, Ana M ^a   Ochoa, Alejandra ^a   Gutiérrez Ospina, Gabriel ^a   López Barrera, Fernando ^a   Barrios, Fernando A ^a   Berger, Peter ^e   Martínez De La Escalera, Gonzalo ^a   Clapp, Carmen ^a,d  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSIDAD DE BOYACÁ   (Colombia)

^d CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; CORNEA VASCULARIZATION; HORMONE RECEPTOR INTERACTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CORNEA; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; FIBROBLAST GROWTH FACTOR 2; IMMUNOENZYME TECHNIQUES; MALE; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; PROLACTIN; RATS; RATS, WISTAR; RECEPTORS, PROLACTIN;

EID: 0342522141     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Battegay BJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
2. Folkman J. Angiogenesis in cancer, vascular rheumatoid arthritis and other diseases. Nat Med. 1995;1:27-31.
3. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessels formation. Trends Biochem Sci. 1997;22:251-256.
4. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther. 1994;63:265-311.
5. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. In: Goldberg ID, Rosen EM, eds. Regulation of Angiogenesis. Basel: Birkhäuser Verlag; 1997:1-8.
6. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990;248:1408-1410.
7. Clapp C, Martínez de la Escalera G. Prolactins: novel regulators of angiogenesis. News Physiol Sci. 1997;12:231-237.
8. Ferrara N, Clapp C, Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology. 1991;129: 896-900.
9. Clapp C, Weiner R. A specific, high-affinity, saturable binding site for the 16-kDa fragment of prolactin on capillary endothelial cells. Endocrinology. 1992;130:1380-1386.
10. Clapp C, Martial JA, Rentier-Delrue F, Guzman R, Weiner R. The 16-kDa N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993;133:1292-1299.
11. Lee H, Struman I, Clapp C, Martial J, Weiner R. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology. 1998;139:3696-3703.
12. Clapp C, Torner L, Gutiérrez-Ospina G, et al. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14 kDa fragment with activity like 16-kDa prolactin. Proc Natl Acad Sci USA. 1994;91:10384-10388.
13. Jackson D, Volpert OV, Bouck N, Linzer DIH. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin related protein. Science. 1994;266:1581-1584.
14. Auerbach R, Auerbach W, Polakowski I. Assay for angiogenesis: a review. Pharmacol Ther. 1991;51:1-11.
15. Dueñas Z, Torner L, Corbacho A, et al. Effects of 16 kDa prolactin antibodies on in vivo angiogenesis (abstract). Endocr Soc. 1998; 80:308. Abstract P2-268.
16. Clapp C. Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms. Endocrinology. 1987;121:2055-2064.
17. Staindl B, Berger P, Kofler R, Wick G. Monoclonal antibodies against human, bovine and rat prolactin: epitope mapping of human prolactin and development of a two-site immunoradiometric assay. J Endocrinol. 1987;114:311-318.
18. Okamura H, Zachwieja J, Raguei S, Kelly P. Characterization and applications of monoclonal antibodies to the prolactin receptor. Endocrinology. 1989;124:2499-2508.
19. Baglia AL, Cruz D, Shaw JE. An Epstein-Barr virus-negative Burkitt lymphoma cell line (sfRamos) secretes a prolactin-like protein during continuous growth in serum-free medium. Endocrinology. 1991;128:2266-2272.
20. Signorella A, Hymer WC. An enzyme-linked immunosorbent assay for rat prolactin. Anal Biochem. 1984;136:372-381.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
22. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. Methods Enzymol. 1991;198:440-450.
23. Frey WH, Nelson JD, Frick ML, Elde RP. Prolactin immunoreactivity in human tears and lacrimal gland: possible implication for tear production. In: Holly FJ, ed. The Preocular Tear Film in Health, Disease, and Contact Lens Wear. Lubbock, TX: The Dry Eye Institute; 1986:798-807.
24. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
25. Takagi H, King LG, Ferrara N, Aiello P. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:1311-1321.
26. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1990;108: 869-872.
27. Meyer-Schwickerath R, Pfeiffer A, Blum WK, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding protein 2 and 3, increased in neovascular eye disease: studies in non-diabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
28. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
29. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;882:277-285.
30. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA. 1995;92:7799-7803.
31. Sakamato N, Iwahana M, Tanaka NG, Osaka Y. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res. 1991;51:903-906.
32. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 1990;87:6624-6628.
33. Torner L, Mejía S, López-Gómez F, et al. A 14 kDa prolactin-like fragment is secreted from the hypothalamo-neurohypophyseal system of the rat. Endocrinology. 1995;136:5454-5460.
34. Clapp C, López-Gómez FJ, Nava G, et al. Expression of prolactin mRNA and prolactin-like proteins in endothelial cells: evidence for autocrine effects. J Endocrinol. 1998;158:137-144.
35. Corbacho A, Macotela Y, Torner L, et al. Synthesis and secretion of prolactin-like proteins in endothelial cells (abstract). Endocr Soc. 1997;79:465. Abstract P3-116.
36. Ochoa A, Dueñas Z, Corbacho A, et al. Isolation, culture and characterization of rat retinal endothelial cells. Evidence for the expression of prolactin by retinal endothelium (abstract). Endocr Soc. 1998;80:76. Abstract OR18-4.
37. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-a-induced angiogenesis. Science. 1995;268:567-569.
38. D'Angelo G, Struman I, Martial JA, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA. 1995;92:6374-6378.
39. Weiner RI, D'Angelo G. Signaling for the antiangiogenic action of 16 k prolactin. Proc Am Assoc Cancer Res. 1996;37:667-668.
40. Caicedo R, Nava G, Dueñas Z, et al. Determinación de prolactina y su ARN mensajero en tejidos y fluídes oculares de pacientes con retinopatía del prematuro (abstract) Mex Pbysiol Sci Soc. 1998;41: 89. Abstract O-107.
41. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly P. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225-268.
42. Crim JW. Prolactin-thyroxine antagonism and the metamorphosis of visual pigments in Ranna catesbeiana tadpoles. J Exp Zool. 1975;192:355-362.
43. Mircheff AK, Warren AW, Wood RL, Tortoriello PJ, Kaswang RL. Prolactin localization, binding, and effects on peroxidase release in rat exorbital lacrimal gland. Invest Ophthalmol Vis Sci. 1992;33: 641-650.
44. Huang ZM, Low A, Azzarolo AM, Mircheff AK, Warren DW. Regulation of prolactin (PRL) messenger RNA in rabbit lacrimal glands. [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1997;39(4)S88G. Abstract nr 4099.
45. Josefsberg Z, Posner BI, Patel B, Bergeron JJ. The uptake of prolactin into female rat liver. J Biol Chem. 1979;254:209-214.
46. Seddiki T, Ollivier-Boousquet M. Temperature dependence of prolactin endocytosis and casein exocytosis in epithelial mammary cells. Eur J Cell Biol. 1991;55:60-70.